Bionano Genomics is a biotechnology company that has been on the scene since 2003. The firm is dedicated to revolutionizing genomics with its Saphyr system, designed for ultra-sensitive and ultra-specific detection of structural variations in DNA. These variations, including insertions, deletions, inversions, and translocations, are vital in understanding various genetic disorders and diseases, such as cancer.
The Saphyr system utilizes optical genome mapping (OGM) technology to analyze long DNA molecules, enabling direct visualization and examination of structural variations without the need for sequencing. This breakthrough approach provides valuable insights into disease mechanisms, genetic disorders, and personalized treatment strategies.
The company received a significant $18.00M Post-IPO Debt investment on 28 May 2024. This latest investment showcases the investor confidence in Bionano Genomics' technology and its potential impact on the biotechnology industry.
Taxonomy:
Genome Mapping, Structural Variation Detection, DNA Analysis, Genetic Disorders, Cancer Research, OGM Technology, Biomarker Discovery, Rare Diseases, Personalized Treatment, Single-Molecule Imaging, Copy Number Variation, Next Generation Cytogenetics, Human Genetics, De Novo Assembly
